ArticleLeukemia & lymphoma2017

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.

Beata Holkova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.